<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768244</url>
  </required_header>
  <id_info>
    <org_study_id>covid1</org_study_id>
    <nct_id>NCT04768244</nct_id>
  </id_info>
  <brief_title>Impact of Maternal COVID-19 Disease on Breast Milk and Infant Health</brief_title>
  <acronym>MilkCorona</acronym>
  <official_title>Impact of Maternal SARS-CoV-2 Infection and Vaccination on Breast Milk Antibodies, Milk Bioactive Compounds and Maternal-child Health (MilkCORONA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Agrochemistry and Food Technology, National Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INCLIVA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clínico Universitario de Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Doctor Peset</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad de Granada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitat Jaume I</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sant Joan de Deu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fetal Medicine Research Center, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigación Sanitaria Aragón</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Agrochemistry and Food Technology, National Research Council</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      prospective multicenter study The main aim is to study the impact of maternal COVID-19 on&#xD;
      breast milk immune, microbiological, and metabolic profile and infant growth and development&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 RNA</measure>
    <time_frame>1 month</time_frame>
    <description>levels of viral RNA from SARS-CoV-2 in breast milk</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>breast milk immune</measure>
    <time_frame>1st year</time_frame>
    <description>interleukines, cytokines and growth factors, immunoglobulins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>breast milk microbiota</measure>
    <time_frame>1st year</time_frame>
    <description>microbiota composition and diversity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>breast milk metabolite</measure>
    <time_frame>1st year</time_frame>
    <description>metabolite profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infant microbiota</measure>
    <time_frame>1st year</time_frame>
    <description>infant microbiota profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infant growth and development</measure>
    <time_frame>1st year</time_frame>
    <description>z-scores growth curves</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVID19</arm_group_label>
    <description>- Women with SARS-CoV-2 infections</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>maternal SARS-CoV-2 infection</intervention_name>
    <description>positive PCR in nasopharinx and/or presence of antibodies in serum</description>
    <arm_group_label>COVID19</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with SARS-CoV-2 infection at the end of pregnancy, before delivery following&#xD;
        hospitals COVID19 screening protocols.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pregnant or nursing women with positive PCR for SARS-CoV-2 in nasopharynge and/or&#xD;
             presence of SARS-CoV-2 antibodies in serum determined in hospitals&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  aggravation of symptomatology requiring specific treatment and/or hospitalization&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women at the end of the pregnancy and also, lactating women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fundacion Investigacion Sanitaria INCLIVA</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Martinez-Costa, MD, PhD</last_name>
      <phone>+34 961973913</phone>
      <email>Cecilia.Martinez@uv.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico la Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Agrochemistry and Food Technology, National Research Council</investigator_affiliation>
    <investigator_full_name>Maria Carmen Collado</investigator_full_name>
    <investigator_title>PhD, Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Breast milk</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Sars-CoV-2</keyword>
  <keyword>metabolites</keyword>
  <keyword>immune compounds</keyword>
  <keyword>infant growth and development</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

